Issue 27, 2014

Nano graphene oxide–hyaluronic acid conjugate for target specific cancer drug delivery

Abstract

A nano graphene oxide–hyaluronic acid (NGO–HA) conjugate was successfully prepared for target specific delivery of an anti-cancer drug loaded by π–π stacking via HA receptor mediated endocytosis. In vitro tests confirmed the pH dependent drug release and target specific anti-cancer effect of the complex.

Graphical abstract: Nano graphene oxide–hyaluronic acid conjugate for target specific cancer drug delivery

Supplementary files

Article information

Article type
Communication
Submitted
21 Jan 2014
Accepted
05 Mar 2014
First published
07 Mar 2014

RSC Adv., 2014,4, 14197-14200

Nano graphene oxide–hyaluronic acid conjugate for target specific cancer drug delivery

H. S. Jung, M. Lee, W. H. Kong, I. H. Do and S. K. Hahn, RSC Adv., 2014, 4, 14197 DOI: 10.1039/C4RA00605D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements